Inhibitors to Factor VIII in a Family with Mild Hemophilia: Molecular Characterization and Response to Factor VIII and Desmopressin

Summary

Inhibitor development in patients with mild hemophilia is a rare event. We report the occurrence of a persistent, high-responding inhibitor in two affected members of a mild hemophilia A family and discuss the therapeutic approaches employed in these patients in terms of their efficacy and effect on antibody titer. Desmopressin was an effective option for bleeding management, because endogenous factor VIII released by DDAVP was less immunogenic than exogenous factor VIII replacement, which invariably triggered anamnestic responses. Genetic analysis performed to investigate whether or not a peculiar molecular lesion accounted for this particular phenotype identified a G-A transversion at nucleotide 6507 in exon 23. This missense mutation has been already described in mild hemophilia A, but not in patients with inhibitors.

• References

• 1 Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. The Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A – Safety, efficacy, and development of inhibitors N Engl J Med 1993; 328: 453-459
• 2 Beck P, Giddings JC, Bloom AL. Inhibitor of factor VIII in mild haemophilia. Br J Haematol 1969; 17: 283-288
• 3 Strauss HS. Acquired circulating anticoagulants in hemophilia A. N Engl J Med 1969; 281: 866-873
• 4 Crowell EB. A factor VIII inhibitor in a mild hemophiliac. Am J Med Sci 1970; 260: 261-263
• 5 Robboy SJ, Lewis EJ, Schun PH, Colman RW. Circulating anticoagulants to factor VIII. Am J Med 1970; 49: 742-752
• 6 Lechner K, Ludwig E, Niessner H, Thaler E. Factor VIII inhibitor in a patient with mild hemophilia A. Haemostasis 1973; 1: 261-270
• 7 Shapiro SS, Hultin M. Acquired inhibitors to coagulation factors. emin Thromb Hemosl 1975; 1: 336-385
• 8 Lowe GD O, Harvic A, Forbes CD, Prentice CR M. Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor. Br Med J 1976; 2: 1110-1110
• 9 Kesteven PJ, Holland IJ, Lawrie AS, Savidge GF. Inhibitor to factor VIII in mild haemophilia. Thromb Hacmost 1984; 52: 50-52
• 10 Bovill EG, Bums SL, Golden EA. Factor VIII antibody in a patient with mild haemophilia. Br J Haematol 1985; 61: 323-328
• 11 Capel P, Toppel M, Van Remoortel E, Fondu P. Factor VIII inhibitor in mild haemophilia (letter). Br J Haematol 1986; 62: 786-787
• 12 Biggs R, Austen DK G, Denson KW K, Borrett R, Rizza CR. The mode of action of antibodies which destroy factor VIII. H. Antibodies which give complex concentration graphs Br J Haematol 1972; 23: 137-155
• 13 Hardisty RM, Maepherson JC. A one-stage factor VIII (anti-hacmophilic globulin) assay and its use on venous and capillary plasma. Thrombos Diathcs Haemorrh 1962; 7: 215-221
• 14 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni JC, Green D, Hampton JR, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diathcs Haemorrh 1975; 34: 869-872
• 15 Gatti L, Mannucei PM. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost 1984; 51: 379-384
• 16 Chomczynski P, Sacchi N. Single-step method of RNA extraction by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochcm 1987; 162: 156-159
• 17 Naylor JA, Green PM, Montandon AJ, Rizza CR, Giannclli F. Detection of three novel mutations in two hemophilia A patients by rapid screening of the whole essential region of factor VIII. Lancet 1991; 337: 635-639
• 18 Montandon AJ, Green PM, Giannelli F, Bentley DR. Direct detection of point mutations by mismatch analysis: application to hemophilia B. Nucleic Acid Res 1989; 17: 3347-3358
• 19 Green PM, Bentley DR, Mibashan RS, Nilsson IM, Giannelli F. Molecular pathology of hemophilia B. EMBO J 1989; 8: 1067-1072
• 20 Lowe G, Pettigrew A, Middleton S, Forbes CD. Prentice CRM. DDAVP in haemophilia Lancet 1977; 2: 614-615
• 21 Millar DS, Sternbrecher RA, Weland K, Grundy CB, Martinowitz U, Krawczak M, Zoll B, Whitmore D, Stephenson J, Mibashan RS, Kakkar VV, Cooper DN. The molecular genetic analysis of haemophilia A: characterization of six partial deletions of the factor VIII gene. Hum Genet 1990; 86: 219-227
• 22 Tuddenham EG D, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne JM, Giannelli F, Antonarakis SE, Cooper DN, Haemophilia A. database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 1994; 22: 3511-3533
• 23 Tizzano EF, Altisent C, Tusell J, Domenech M, Baiyet M. Intron 22 inversions and haemophilia (letter). Lancet 1994; 343: 792
• 24 Goodeve AC, Preston FE, Peake IR. Factor VIII gene rearrangements in patients with severe haemophilia A. Lancet 1994; 343: 329-330